Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Immuno Cure Acquires Partner Teresa Healthcare, an Electroporation Company

publication date: Sep 20, 2022

Immuno Cure, a Hong Kong biotech focused on DNA vaccines and immunotherapies, acquired 92.6% of Shanghai Teresa Healthcare, an electroporation company. Teresa’s EP device delivers brief electrical pulses to improve penetration of DNA vaccines through cell membranes to increase gene expression and immune responses. Immuno Cure already uses Teresa’s technology to deliver its two PD-1-Enhanced DNA vaccines, currently in clinical trials. Immuno Cure will pay for most of the transaction in cash. Teresa shareholders will also receive 1.5% equity in Immuno Cure, and the inventor of Teresa's EP technology, Professor Yuhong Xu, will continue to own her 7.4% stake in Teresa. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital